Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 2

recruiting
3 974
countries
28
conditions
2 106

39 trials match your criteria

Neoplasm

Recruiting

Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Non-small cell lung cancer

Not yet recruiting

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Lung cancer metastatic

Not yet recruiting

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Lung adenocarcinoma

Not recruiting

Durvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Carboplatin

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate

Lung neoplasm malignant

Not recruiting

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Pleural mesothelioma malignant

Not recruiting

Study of Pembrolizumab with Cisplatin or Carboplatin and Pemetrexed for Patients with Resectable Malignant Pleural Mesothelioma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Non-small cell lung cancer

Not recruiting

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.